The 5 constituents in the munKNEE Psychedelic Drug Stocks Index are DOWN 29.2%, on average, so far in 2023 and are now DOWN 85.9% from their highs in 2021. Below is how each constituent stock has performed so far in December, in descending order and YTD:
- is focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
- is focused on the use of ketamine, DMT and ibogaine. Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
- is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and here for much more extensive information on MNMA.
- is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
- is researching and developing therapies and products with the world’s largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
Summary
The munKNEE Psychedelic Drug Stocks Index is UP 9.1% MTD but is still DOWN 29.2% YTD. The AdvisorShares Psychedelic ETF (PSIL), in comparison, is UP 9.2% MTD but is “only” DOWN 22.4% YTD.More By This Author:American Cannabis MSO Stocks Index Has Rebounded In 2023
An Atrocious Year For Canadian Cannabis LP Stocks Index: Down 64% YTD
What’s Cloud Computing? How Have The Top 8 Companies Done YTD?
Leave A Comment